Income StatementBalance SheetCash FlowSegments
Enbridge logo

Enbridge Cash Flow Statement

Operating, investing, and financing cash movements

Enbridge generated $11.6B in operating cash flow over the trailing twelve months. After $9.7B in capital expenditures, free cash flow was $1.9B. Free cash flow decreased 0.6% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$11.6BNet Cash From Investing (TTM)-$11.5BNet Cash From Financing (TTM)-$339.0MCapital Expenditures (TTM)$9.7BDepreciation And Amortization Cf (TTM)$5.7BNet Change In Cash (TTM)-227,700,000,000.0%
Latest FilingQ1 2026
Report Date2026-05-08
Market Cap$126.74B
P/E Ratio18.36
ROE10.37%

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other non-cash income (expense)-$20.0M-$14.0M$58.0M$47.0M-$213.0M$33.0M
Other non-cash income (expense)-$20.0M-$14.0M$58.0M$47.0M-$213.0M$33.0M
Deferred income taxes$0.0$304.0M$487.0M$153.0M$81.0M$271.0M
Depreciation and amortization$1.4B$1.4B$1.4B$1.4B$1.5B$1.4B
Other Non-Cash Income (Expense)-$20.0M-$14.0M$58.0M$47.0M-$213.0M$33.0M
Other Non-cash Income (Expense)-$20.0M-$14.0M$58.0M$47.0M-$213.0M$33.0M
Other Non-cash Income (Expense)-$20.0M-$14.0M$58.0M$47.0M-$213.0M$33.0M
Net cash from operating activities$3.7B$3.1B$3.2B$2.9B$3.1B$2.3B
Net income$618.0M$2.5B$2.3B$847.0M$2.1B$1.8B
Other non-cash income (expense)-$20.0M-$14.0M$58.0M$47.0M-$213.0M$33.0M
Adjustment For Income Loss Of Equity Method Investments-$640.0M-$729.0M-$510.0M-$451.0M-$534.0M-$541.0M
Distributions of earnings from equity method investees$622.0M$557.0M$502.0M$488.0M$519.0M$462.0M
Impairment charges for facilities consolidation$190.0M$0.0$330.0M$0.0$240.0M—
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital—$899.0M——$666.0M$1.9B
Other Noncash Income (Expense)-$20.0M-$14.0M$58.0M$47.0M-$213.0M$33.0M
Gain (loss) on mark-to-market of Escrowed Shares-$1.3B$92.0M$1.3B—$337.0M-$893.0M
Other Non-cash Income and Expense-$20.0M-$14.0M$58.0M$47.0M-$213.0M$33.0M
Gain on Partial Sale of Investment$681.0M$130.0M—$219.0M—$0.0
Other Non-Cash Adjustments-$20.0M-$14.0M$58.0M$47.0M-$213.0M$33.0M
Other Non-Cash Income and Expense-$20.0M-$14.0M$58.0M$47.0M-$213.0M$33.0M

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquisitions, net of cash acquired$407.0M$0.0$0.0$0.0$0.0—
Capital expenditures$2.5B$1.7B$1.9B$2.3B$3.0B$2.4B
Payment for (Proceeds from) Other Investing Activity$7.0M$16.0M$19.0M$6.0M$5.0M$20.0M
Payments to Acquire Intangible Assets$62.0M$60.0M$64.0M$91.0M—$76.0M
Payments to Acquire Long-Term Investments$1.6B$304.0M$1.1B$487.0M$455.0M$503.0M
Sales of and distributions from equity method investments$681.0M$130.0M—$219.0M—$0.0
Proceeds from Sale of Equity Method Investments$681.0M$130.0M—$219.0M—$0.0
Proceeds from Sale of Equity Method Investments$681.0M$130.0M—$219.0M—$0.0
Net cash from investing activities-$4.4B-$1.8B-$2.9B-$2.5B-$3.3B-$2.8B
Dividend Received from Consumer Healthcare JV$139.0M$184.0M$200.0M$147.0M$150.0M$213.0M
Proceeds from Partial Sale of Haleon Investment$681.0M$130.0M—$219.0M—$0.0
Payments for Deposits$62.0M$60.0M$64.0M$91.0M—$76.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from minority shareholders—$5.0M$2.0M$1.0M$2.0M$6.0M
Repayments of debt$1.0B$2.7B$1.3B$2.0B$735.0M$67.0M
Distributions to noncontrolling interests$87.0M$100.0M$95.0M$81.0M$84.0M$82.0M
Dividends paid$2.0B$2.1B$2.1B$2.1B$2.1B$2.1B
Distributions To Redeemable Noncontrolling Interest$0.0$0.0———$17.0M
Payments of Ordinary Dividends, Preferred Stock and Preference Stock$101.0M$102.0M$104.0M$105.0M$108.0M$107.0M
Proceeds From Investment By Redeemable Noncontrolling Interest In Subsidiary Net Of Transaction Costs$0.0$178.0M$178.0M$178.0M$178.0M—
Proceeds From Issuance Of Long Term Debt Net Of Issuance Costs$932.0M$2.8B$3.8B$1.8B$2.6B$4.7B
Other, net-$9.0M-$36.0M$0.0-$8.0M-$44.0M-$54.0M
Proceeds From Redeemable Noncontrolling Interest$0.0$0.0———$6.0M
Proceeds From Repayments Of Commercial Paper And Lines Of Credit$3.3B$967.0M-$1.5B$1.3B$508.0M-$1.7B
Proceeds from (Repayments of) Short-Term Debt—$330.0M$55.0M$360.0M—$458.0M
Net proceeds from sales of subsidiary shares—$5.0M$2.0M$1.0M$2.0M$6.0M
Payment of Deferred Purchase Consideration-$9.0M-$36.0M$0.0-$8.0M-$44.0M-$54.0M
Noncontrolling interest transactions and other-$9.0M-$36.0M$0.0-$8.0M-$44.0M-$54.0M
Proceeds from related party debt$0.0$0.0$25.0M$14.0M$2.0M$30.0M
Proceeds from Minority Shareholders—$5.0M$2.0M$1.0M$2.0M$6.0M
Proceeds from Sale of Noncontrolling Interests—$5.0M$2.0M$1.0M$2.0M$6.0M
Net cash from financing activities$601.0M-$950.0M-$1.2B-$126.0M-$108.0M$1.1B
Noncontrolling Interests Activity and Other-$9.0M-$36.0M$0.0-$8.0M-$44.0M-$54.0M
Proceeds from Minority Shareholders—$5.0M$2.0M$1.0M$2.0M$6.0M
Proceeds from issuance of common stock—$5.0M$1.0M$2.0M$20.0M$0.0
Proceeds from Minority Shareholders—$5.0M$2.0M$1.0M$2.0M$6.0M
Net Change in Short-term Borrowings and Indebtedness to Subsidiaries—$330.0M$55.0M$360.0M—$458.0M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$1.1B$1.3B$1.3B$547.0M$82.0M-$97.0M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash8300000000.0%800000000.0%-6300000000.0%—-1900000000.0%2200000000.0%
Net increase (decrease) in cash-10200000000.0%32200000000.0%-90000000000.0%—-33200000000.0%65000000000.0%

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interest paid$1.0B$1.2B$1.2B$1.2B$1.2B—